Description: A 20mg Retatrutide pen, as seen in research contexts, typically contains lyophilized powder for reconstitution, intended for subcutaneous injection (e.g., arm, thigh, stomach). It is often cold-shipped and stable for up to a year when refrigerated (2–8°C). These pens are labeled for "research only" and not for human consumption.
Mechanism: Retatrutide activates GLP-1, GIP, and glucagon receptors, suppressing appetite, slowing digestion, boosting fat metabolism, and improving insulin sensitivity. Phase 2 trials showed up to 24–25% body weight loss over 48 weeks, surpassing drugs like semaglutide.
Dosage: No standardized dosing for clinical use exists. Research trials use doses starting at 1mg, titrating up to 5–15mg weekly. A 20mg pen would require precise reconstitution and dosing, typically managed by researchers, not individuals.
